SEC Form 4 · accession 0001171843-16-011868
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank A Holler
Director
Period of report
Aug 16, 2016
Accepted (ET)
Aug 18, 2016 · 8:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Aug 16, 2016 | S | 6,863 | $8.25 | D | 169,006 | D | |
| Common SharesF1 | Aug 17, 2016 | S | 1,600 | $7.89 | D | 167,406 | D | |
| Common SharesF2 | Aug 18, 2016 | S | 9,599 | $7.70 | D | 157,807 | D | |
| Common Shares | holding | — | — | — | 1,184 | I | By Spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $7.89 to $7.90 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F2The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $7.70 to $7.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.